A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)

Administered By

Awarded By

Contributors

Start/End

  • July 9, 2019 - August 5, 2024